Study summary
Adding a bispecific antibody to standard chemo cut the risk of progression in half for higher-risk patients
51%lower risk of progression or death
What was tested
Epcoritamab, a bispecific antibody, added to R-CHOP chemotherapy, against R-CHOP alone, as first treatment for newly diagnosed DLBCL with higher-risk scores.
What they found
- The combination cut the risk of progression or death by 51%, meeting its main goal.
- Full survival data and FDA review are still ahead.
What it means
The first bispecific-antibody combination to clearly improve on standard chemo as a first treatment for higher-risk DLBCL.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.